Tag: plans

SAN JUAN CAPISTRANO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG or “Ensign”), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that Christopher Christensen, Executive Chairman and member of the Ensign Board of Directors, has provided notice to the board of his intent to retire from both his roles effective September 1, 2025.

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT

ROSEMONT, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation ("Wintrust") (Nasdaq: WTFC) today announced it will release second quarter and year-to-date 2025 earnings results after the market closes on Monday, July 21, 2025 and host a conference call on Tuesday, July 22, 2025 at 10:00 a.m. (CDT).

Virtual webinar on June 23, 2025 at 8:00 am ET

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (“NHP”) announced today that it declared quarterly dividends on its outstanding preferred stock. Specifically, NHP declared a dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock payable on July 15, 2025 to holders of record at the close of business on July 3, 2025. In addition, NHP declared a dividend of $0.4453125 per share on its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock payable on July 15, 2025 to holders of record at the close of business on July 3, 2025.

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.

The price of XRP has fluctuated violently, rising to $2.20 before falling back to about $2.15, affected by market's risk aversion. At the same time, the stablecoin RLUSD launched by Ripple was approved by Dubai, which strengthened its confidence in global expansion; a Chinese institution plans to invest $300 million in the purchase of XRP, highlighting its rising appeal. In addition, the dispute between Trump and Musk has also brought volatility to the market. XRP is still hovering around the key support level of $2.00, and the future direction depends on legal progress and ETF approval.

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules